Is Breztri Aerosphere approved by the FDA for maintenance treatment of Chronic Obstructive Pulmonary Disease?

Breztri Aerosphere is a combination inhaler containing budesonide (an inhaled corticosteroid), glycopyrrolate (an anticholinergic), and formoterol fumarate (a long-acting beta2-agonist). The U.S. Food and Drug Administration (FDA) has approved it specifically for the maintenance (long-term) treatment of chronic obstructive pulmonary disease (COPD). This means it is meant to be used regularly to help control symptoms and prevent flare-ups, not for sudden breathing problems.

What the research says

According to the FDA-approved prescribing information, Breztri Aerosphere is indicated for the maintenance treatment of patients with COPD ³. The approval is based on clinical trials showing that the triple combination improves lung function and reduces exacerbations compared to some dual therapies. The FDA also specifies that Breztri Aerosphere is not indicated for the relief of acute bronchospasm (sudden shortness of breath) or for the treatment of asthma ³. Other sources in this set do not directly address Breztri Aerosphere's approval, but they provide context on COPD management: for example, biologic therapies like dupilumab can reduce exacerbations in certain patients ², and pulmonary rehabilitation with balance training improves quality of life ¹. However, these do not change the fact that Breztri Aerosphere is an approved maintenance treatment for COPD.

What to ask your doctor

• Is Breztri Aerosphere a good option for my COPD maintenance therapy?
• How does Breztri Aerosphere compare to other inhalers I might be using?
• What side effects should I watch for with this triple-combination inhaler?
• Should I continue using a rescue inhaler for sudden symptoms while on Breztri Aerosphere?
• Are there any specific conditions or medications that would make Breztri Aerosphere less safe for me?